[email protected]

USA: +1 347 690-0211 | UK: +44 2032 894158 | Translate : 

Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports
  1. Home
  2. Healthcare
  3. Urinary Tract Infection Therapeutics Market

Urinary Tract Infection Therapeutics Market Size, Share Global Analysis Report, , 2021-2027

report img

Urinary Tract Infection Therapeutics Market- By Age Group (Children, Adults & Elderly), By Indication (Complicated, Uncomplicated, Recurrent, Catheter-related), By Distribution Network (E-commerce, Hospital Pharmacies, Retail Pharmacies), By Drug Group (Azoles and Amphotericin B, Cephalosporin, Quinolones, Nitrofurans, Penicillin & Combinations, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021-2027

Industry Insights

[215+ Pages Research Report] According to Facts and factors, The global Urinary Tract Infection Therapeutics Market was worth about USD 8,935 million in 2020 and is predicted to grow to around USD 11,652 million by 2027, with a compound annual growth rate (CAGR) of around 4.56%. The research includes a global and regional forecast and analysis of the urinary tract infection therapeutics market. It also provides a comprehensive analysis, market growth & forecast, trends, potential drivers, and constraints. In addition, the report examines global opportunities in the urinary tract infection therapeutics market from 2021 to 2027.

logoMarket Overview

Urinary tract infections can affect both the lower and upper urinary tract lines. Bacterial infection has the potential to infect and damage the area. If there is an infection in the urinary tract, pain is common during urination. Urinary infections can be caused by a number of different circumstances. It is an illness that affects a large number of people. However, this virus has a significant death rate. There are certain medications, treatments, and indication segments that generate a lot of interest. Infection can be caused by frequent urination even when the bladder is empty. Obesity and diabetes are two of the most prominent causes of these infections.

The global urinary tract infection therapeutics market is in great demand as the number of cases of UTI is rising constantly. This infection in the urinary tract affects a large percentage of females. This condition affects more than half of the female population. In recent years, 1 million people have been admitted to hospitals due to UTIs. Kidney stones, according to urological developments, are key contributors impacting urological health. Urinary tract infections are more common in patients with renal disease and stones. These factors will result in a high rate of UTI treatments in the coming years.

Urinary Tract Infection Therapeutics Market

To know more about this report | Request Free Sample Copy

logoIndustry Growth Factors

Urinary tract infection can affect kidneys, urethra, bladder, and prostate gland. It is thought that using clean toilets will avoid such diseases. Another element that helps to prevent this infection is maintaining good intimate hygiene. Because of the high prevalence of these infections, UTI therapy is widely used. In addition, the introduction of combination medications is a key factor for market growth.

These infections respond well to combination medications. The availability of such a diverse spectrum of medications is predicted to increase the demand for UTI therapy. The industry is in great demand due to the growing geriatric population, since such infections are very common among the elderly. UTI is a common problem among older women over the age of 65. The UTI treatment industry will benefit from the increase in the elderly population. All of these global urinary tract infection therapeutics market drivers will contribute to its remarkable growth rate.

The market for urinary tract infection therapeutics will expand as new products enter the market. The market's end-user base will grow as a result of innovation and new product releases. The new product also improves the application of urinary tract infection treatment. To effectively cure infections, the leading players are inventing novel therapies and formulations using effective materials. Customers will have a wide selection of treatment options as a result of these upcoming market advances.

Key players are launching medications that break down infectious cells. This advancement will ensure that the patient is not affected by UTI infections in the future. The supply of UTI therapies will increase as a result of this growth factor. Penicillin and combination medications are expected to gain popularity in numerous locations. Furthermore, the leading players are working on new growth tactics. During the projection period, the production of UTI treatment medications will increase dramatically. Many end-users will be attracted to the launch of a wide choice of UTI medicines. All of these things will add to the market's high revenue rates.

logoSegmentation Analysis

The candle market is segmented based on age group, indication, distribution network, drug group, and region:   

As per age group, the urinary tract infection therapeutics market is segmented into Children, Adults & Elderly. On the basis of indication, the market is segregated into Complicated, Uncomplicated, Recurrent, and Catheter-related. Further, the market is divided on the basis of distribution network such as E-commerce, Hospital Pharmacies, and Retail Pharmacies. On the basis of drug group the market is divided into Azoles and Amphotericin B, Cephalosporin, Quinolones, Nitrofurans, Penicillin & Combinations, and Others.

logoReport Scope

Report Attribute

Details

Market Size in 2020

USD 8,935 Million

Projected Market Size in 2027

USD 11,652 Million

CAGR Growth Rate

4.56% CAGR

Base Year

2020

Forecast Years

2021-2027

Key Market Players

Achaogen, Allergen, Aquinox, AstraZeneca, Almirall, S.A, Bayer AG, Bristol-Myers Squibb Company, Cipla, C.H. Boehringer Sohn, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche, GlaxoSmithKline plc., Janssen Global Services, LLC, Lipella Pharmaceuticals, Lupin Ltd., MediciNova, MerLion Pharmaceuticals, Merck & Co., Inc, Novo Nordisk, Novartis, Pfizer, Sun Pharmaceutical Industries, Shionogi, Teva Pharmaceutical Industries, Urigen, Zavante Therapeutics, and Others

Key Segment

By Age Group, By Indication, By Distribution Network, By Drug Group, and By Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logoRegional Analysis

Diagnostic and innovative treatments will boost growth in North America for the urinary tract infection therapeutics market. In addition, the United States and Canada will make the most investments in UTI treatments. UTI medications are effective in treating serious bacterial infections in the urinary system.

In addition, Asia appeases to be another big competitor with a significant market share. There is an increasing demand for UTI treatment. The expansion of health infrastructure contributes to overall growth. In addition, new product launches will result from developments. In the Asia Pacific, the prevalence of UTIs is greater. Europe is the next greatest region in terms of UTI treatment expansion. The market has a strong growth potential, which will result in new advancements in the coming years.

The market for global urinary tract infection therapeutics is dominated by a few major competitors. The completion will be intense with new product developments. Major companies in the global market are raising product awareness in a variety of locations. These public awareness campaigns will increase the number of people who use UTI medications. In addition, market acquisitions, growth, and alliances will be prevalent during the projected period.

logoCompetitive Players

Major players in the global urinary tract infection therapeutics market are

  • Achaogen
  • Allergen
  • Aquinox
  • AstraZeneca
  • Almirall
  • S.A
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla
  • C.H. Boehringer Sohn
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline plc.
  • Janssen Global Services
  • LLC
  • Lipella Pharmaceuticals
  • Lupin Ltd.
  • MediciNova
  • MerLion Pharmaceuticals
  • Merck & Co.Inc
  • Novo Nordisk
  • Novartis
  • Pfizer
  • Sun Pharmaceutical Industries
  • Shionogi
  • Teva Pharmaceutical Industries
  • Urigen
  • Zavante Therapeutics.

The global urinary tract infection therapeutics market is segmented as follows:

logoBy Age Group Segment Analysis

  • Children
  • Adults
  • Elderly

logoBy Indication Segment Analysis

  • Complicated
  • Uncomplicated
  • Recurrent
  • Catheter-related

logoBy Distribution Network Segment Analysis

  • E-Commerce
  • Hospital Pharmacies
  • Retail Pharmacies

logoBy Drug Group Segment Analysis

  • Azoles and Amphotericin B
  • Cephalosporin
  • Quinolones
  • Nitrofurans
  • Penicillin and Combinations
  • Others

logoBy Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Southeast Asia
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Table of Content

  1. Chapter 1 Preface
    1. 1.1. Report Description and Scope
    2. 1.2. Research scope
    3. 1.3. Research methodology
      1. 1.3.1. Market Research Type
      2. 1.3.2. Market research methodology
  2. Chapter 2 Executive Summary
    1. 2.1. Global Urinary Tract Infection Therapeutics Market, (2021 - 2027) (USD Million)
    2. 2.2. Global Urinary Tract Infection Therapeutics Market: snapshot
  3. Chapter 3 Global Urinary Tract Infection Therapeutics Market - Industry Analysis
    1. 3.1. Urinary Tract Infection Therapeutics Market: Market Dynamics
    2. 3.2. Market Drivers
      1. 3.2.1. Rising UTI incidences
      2. 3.2.2. The introduction of combination medications
    3. 3.3. Porter’s Five Forces Analysis
    4. 3.4. Market Attractiveness Analysis
      1. 3.4.1. Market attractiveness analysis By Age Type
      2. 3.4.2. Market attractiveness analysis By Indication
      3. 3.4.3. Market attractiveness analysis By Distribution Network
      4. 3.4.4. Market attractiveness analysis By Drug Group
  4. Chapter 4 Global Urinary Tract Infection Therapeutics Market– Competitive Landscape
    1. 4.1. Company market share analysis
      1. 4.1.1. Global Urinary Tract Infection Therapeutics Market: company market share, 2020
    2. 4.2. Strategic development
      1. 4.2.1. Acquisitions & mergers
      2. 4.2.2. New Product launches
      3. 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      4. 4.2.4. Research and development and Regional expansion
    3. 4.3. Price trend analysis
  5. Chapter 5 Global Urinary Tract Infection Therapeutics – Age Type Analysis
    1. 5.1. Global Urinary Tract Infection Therapeutics Market overview: By Age Type
      1. 5.1.1. Global Urinary Tract Infection Therapeutics Market share, By Age Type, 2020 and 2027
    2. 5.2. Children
      1. 5.2.1. Global Urinary Tract Infection Therapeutics Market by Children, 2021 - 2027 (USD Million)
    3. 5.3. Adults
      1. 5.3.1. Global Urinary Tract Infection Therapeutics Market by Adults, 2021 - 2027 (USD Million)
    4. 5.4. Elderly
      1. 5.4.1. Global Urinary Tract Infection Therapeutics Market by Elderly, 2021 - 2027 (USD Million)
  6. Chapter 6 Global Urinary Tract Infection Therapeutics – Indication Analysis
    1. 6.1. Global Urinary Tract Infection Therapeutics Market overview: By Indication
      1. 6.1.1. Global Urinary Tract Infection Therapeutics Market share, By Indication, 2020 and 2027
    2. 6.2. Complicated
      1. 6.2.1. Global Urinary Tract Infection Therapeutics Market by Complicated, 2021 - 2027 (USD Million)
    3. 6.3. Uncomplicated
      1. 6.3.1. Global Urinary Tract Infection Therapeutics Market by Uncomplicated, 2021 - 2027 (USD Million)
    4. 6.4. Recurrent
      1. 6.4.1. Global Urinary Tract Infection Therapeutics Market by Recurrent, 2021 - 2027 (USD Million)
    5. 6.5. Catheter-related
      1. 6.5.1. Global Urinary Tract Infection Therapeutics Market by Catheter-related, 2021 - 2027 (USD Million)
  7. Chapter 7 Global Urinary Tract Infection Therapeutics – Distribution Network Analysis
    1. 7.1. Global Urinary Tract Infection Therapeutics Market overview: By Distribution Network
      1. 7.1.1. Global Urinary Tract Infection Therapeutics Market share, By Distribution Network, 2020 and 2027
    2. 7.2. E-Commerce
      1. 7.2.1. Global Urinary Tract Infection Therapeutics Market by E-Commerce, 2021 - 2027 (USD Million)
    3. 7.3. Hospital Pharmacies
      1. 7.3.1. Global Urinary Tract Infection Therapeutics Market by Hospital Pharmacies, 2021 - 2027 (USD Million)
    4. 7.4. Retail Pharmacies
      1. 7.4.1. Global Urinary Tract Infection Therapeutics Market by Retail Pharmacies, 2021 - 2027 (USD Million)
  8. Chapter 8 Global Urinary Tract Infection Therapeutics – Drug Group Analysis
    1. 8.1. Global Urinary Tract Infection Therapeutics Market overview: By Drug Group
      1. 8.1.1. Global Urinary Tract Infection Therapeutics Market share, By Drug Group, 2020 and 2027
    2. 8.2. Azoles and Amphotericin B
      1. 8.2.1. Global Urinary Tract Infection Therapeutics Market by Azoles and Amphotericin B, 2021 - 2027 (USD Million)
    3. 8.3. Cephalosporin
      1. 8.3.1. Global Urinary Tract Infection Therapeutics Market by Cephalosporin, 2021 - 2027 (USD Million)
    4. 8.4. Quinolones
      1. 8.4.1. Global Urinary Tract Infection Therapeutics Market by Quinolones, 2021 - 2027 (USD Million)
    5. 8.5. Nitrofurans
      1. 8.5.1. Global Urinary Tract Infection Therapeutics Market by Nitrofurans, 2021 - 2027 (USD Million)
    6. 8.6. Penicillin and Combinations
      1. 8.6.1. Global Urinary Tract Infection Therapeutics Market by Penicillin and Combinations, 2021 - 2027 (USD Million)
    7. 8.7. Others
      1. 8.7.1. Global Urinary Tract Infection Therapeutics Market by Others, 2021 - 2027 (USD Million)
  9. Chapter 9. Company Profiles
    1. 9.1 Achaogen
    2. 9.1.1 Overview
    3. 9.1.2 Financials
    4. 9.1.3 Product Portfolio
    5. 9.1.4 Business Strategy
    6. 9.1.5 Recent Developments
  10. 9.2 Allergen
    1. 9.2.1 Overview
    2. 9.2.2 Financials
    3. 9.2.3 Product Portfolio
    4. 9.2.4 Business Strategy
    5. 9.2.5 Recent Developments
  11. 9.3 Aquinox
    1. 9.3.1 Overview
    2. 9.3.2 Financials
    3. 9.3.3 Product Portfolio
    4. 9.3.4 Business Strategy
    5. 9.3.5 Recent Developments
  12. 9.4 AstraZeneca
    1. 9.4.1 Overview
    2. 9.4.2 Financials
    3. 9.4.3 Product Portfolio
    4. 9.4.4 Business Strategy
    5. 9.4.5 Recent Developments
  13. 9.5 Almirall
    1. 9.5.1 Overview
    2. 9.5.2 Financials
    3. 9.5.3 Product Portfolio
    4. 9.5.4 Business Strategy
    5. 9.5.5 Recent Developments
  14. 9.6 S.A
    1. 9.6.1 Overview
    2. 9.6.2 Financials
    3. 9.6.3 Product Portfolio
    4. 9.6.4 Business Strategy
    5. 9.6.5 Recent Developments
  15. 9.7 Bayer AG
    1. 9.7.1 Overview
    2. 9.7.2 Financials
    3. 9.7.3 Product Portfolio
    4. 9.7.4 Business Strategy
    5. 9.7.5 Recent Developments
  16. 9.8 Bristol-Myers Squibb Company
    1. 9.8.1 Overview
    2. 9.8.2 Financials
    3. 9.8.3 Product Portfolio
    4. 9.8.4 Business Strategy
    5. 9.8.5 Recent Developments
  17. 9.9 Cipla
    1. 9.9.1 Overview
    2. 9.9.2 Financials
    3. 9.9.3 Product Portfolio
    4. 9.9.4 Business Strategy
    5. 9.9.5 Recent Developments
  18. 9.10 C.H. Boehringer Sohn
    1. 9.10.1 Overview
    2. 9.10.2 Financials
    3. 9.10.3 Product Portfolio
    4. 9.10.4 Business Strategy
    5. 9.10.5 Recent Developments
  19. 9.11 Dr. Reddy’s Laboratories Ltd.
    1. 9.11.1 Overview
    2. 9.11.2 Financials
    3. 9.11.3 Product Portfolio
    4. 9.11.4 Business Strategy
    5. 9.11.5 Recent Developments
  20. 9.12 F. Hoffmann-La Roche
    1. 9.12.1 Overview
    2. 9.12.2 Financials
    3. 9.12.3 Product Portfolio
    4. 9.12.4 Business Strategy
    5. 9.12.5 Recent Developments
  21. 9.13 GlaxoSmithKline plc.
    1. 9.13.1 Overview
    2. 9.13.2 Financials
    3. 9.13.3 Product Portfolio
    4. 9.13.4 Business Strategy
    5. 9.13.5 Recent Developments
  22. 9.14 Janssen Global Services LLC
    1. 9.14.1 Overview
    2. 9.14.2 Financials
    3. 9.14.3 Product Portfolio
    4. 9.14.4 Business Strategy
    5. 9.14.5 Recent Developments
  23. 9.15 Lipella Pharmaceuticals
    1. 9.15.1 Overview
    2. 9.15.2 Financials
    3. 9.15.3 Product Portfolio
    4. 9.15.4 Business Strategy
    5. 9.15.5 Recent Developments
  24. 9.16 Lupin Ltd.
    1. 9.16.1 Overview
    2. 9.16.2 Financials
    3. 9.16.3 Product Portfolio
    4. 9.16.4 Business Strategy
    5. 9.16.5 Recent Developments
  25. 9.17 MediciNova
    1. 9.17.1 Overview
    2. 9.17.2 Financials
    3. 9.17.3 Product Portfolio
    4. 9.17.4 Business Strategy
    5. 9.17.5 Recent Developments
  26. 9.18 MerLion Pharmaceuticals
    1. 9.18.1 Overview
    2. 9.18.2 Financials
    3. 9.18.3 Product Portfolio
    4. 9.18.4 Business Strategy
    5. 9.18.5 Recent Developments
  27. 9.19 Merck & Co. Inc
    1. 9.19.1 Overview
    2. 9.19.2 Financials
    3. 9.19.3 Product Portfolio
    4. 9.19.4 Business Strategy
    5. 9.19.5 Recent Developments
  28. 9.20 Novo Nordisk
    1. 9.20.1 Overview
    2. 9.20.2 Financials
    3. 9.20.3 Product Portfolio
    4. 9.20.4 Business Strategy
    5. 9.20.5 Recent Developments
  29. 9.21 Novartis
    1. 9.21.1 Overview
    2. 9.21.2 Financials
    3. 9.21.3 Product Portfolio
    4. 9.21.4 Business Strategy
    5. 9.21.5 Recent Developments
  30. 9.22 Pfizer
    1. 9.22.1 Overview
    2. 9.22.2 Financials
    3. 9.22.3 Product Portfolio
    4. 9.22.4 Business Strategy
    5. 9.22.5 Recent Developments
  31. 9.23 Sun Pharmaceutical Industries
    1. 9.23.1 Overview
    2. 9.23.2 Financials
    3. 9.23.3 Product Portfolio
    4. 9.23.4 Business Strategy
    5. 9.23.5 Recent Developments
  32. 9.24 Shionogi
    1. 9.24.1 Overview
    2. 9.24.2 Financials
    3. 9.24.3 Product Portfolio
    4. 9.24.4 Business Strategy
    5. 9.24.5 Recent Developments
  33. 9.25 Teva Pharmaceutical Industries
    1. 9.25.1 Overview
    2. 9.25.2 Financials
    3. 9.25.3 Product Portfolio
    4. 9.25.4 Business Strategy
    5. 9.25.5 Recent Developments
  34. 9.26 Urigen
    1. 9.26.1 Overview
    2. 9.26.2 Financials
    3. 9.26.3 Product Portfolio
    4. 9.26.4 Business Strategy
    5. 9.26.5 Recent Developments
  35. 9.27 Zavante Therapeutics
    1. 9.27.1 Overview
    2. 9.27.2 Financials
    3. 9.27.3 Product Portfolio
    4. 9.27.4 Business Strategy
    5. 9.27.5 Recent Developments

    List of Figures

    FIG. 1 Global Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 2 Global Urinary Tract Infection Therapeutics Market Share, by Age Group, 2021-2027 (USD Million)
FIG. 3 Global Adults Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 4 Global Elderly Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 5 Global Children Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 6 Global Urinary Tract Infection Therapeutics Market Share, by Indication, 2021-2027 (USD Million)
FIG. 7 Global Uncomplicated UTI Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 8 Global Recurrent UTI Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 9 Global Complicated UTI Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 10 Global CA (Catheter Associated) UTI Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 11 Global Urinary Tract Infection Therapeutics Market Share, by Drug Type, 2021-2027 (USD Million)
FIG. 12 Global Quinolones Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 13 Global Azoles & Amphotericin B Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 14 Global Aminoglycoside Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 15 Global Penicillin & Combinations Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 16 Global Cephalosporin Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 17 Global Nitrofurans Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 18 Global Others Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 19 Global Urinary Tract Infection Therapeutics Market Share, by Distribution Channel, 2021-2027 (USD Million)
FIG. 20 Global Hospital Pharmacies Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 21 Global Retail Pharmacies Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 22 Global E-commerce Urinary Tract Infection Therapeutics Market, 2017-2027 (USD Million)
FIG. 23 Global Urinary Tract Infection Therapeutics Market Share, by Region, 2021-2027
FIG. 24 North America Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 25 U.S. Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 26 Rest of North America Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 27 Europe Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 28 Germany Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 29 France Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 30 U.K. Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 31 Italy Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 32 Spain Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 33 Rest of Europe Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 34 Asia Pacific Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 35 China Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 36 Japan Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 37 India Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 38 South-East Asia Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 39 Rest of Asia Pacific Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 40 Latin America Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 41 Brazil Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 42 Rest of Latin America Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 43 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 44 GCC Countries Urinary Tract Infection Therapeutics Market, 2017-2027
FIG. 45 South Africa Urinary Tract Infection Therapeutics Market, 2017-2027 
FIG. 46 Rest of Middle-East Africa Urinary Tract Infection Therapeutics Market, 2017-2027 
FIG. 47 Competitor Market Share – Revenue 
FIG. 48 Johnson & Johnson Services, Inc. Revenue and Growth Rate 
FIG. 49 Johnson & Johnson Services, Inc. Market Share 
FIG. 50 GlaxoSmithKline Revenue and Growth Rate 
FIG. 51 GlaxoSmithKline Market Share 
FIG. 52 Novartis AG Revenue and Growth Rate 
FIG. 53 Novartis AG Market Share 
FIG. 54 Teva Pharmaceutical Industries Ltd. Revenue and Growth Rate 
FIG. 55 Teva Pharmaceutical Industries Ltd. Market Share 
FIG. 56 Sun Pharmaceutical Industries Ltd. Revenue and Growth Rate 
FIG. 57 Sun Pharmaceutical Industries Ltd. Market Share 
FIG. 58 Pfizer Inc. Revenue and Growth Rate 
FIG. 59 Pfizer Inc. Market Share 
FIG. 60 F. Hoffmann-La Roche Ltd Revenue and Growth Rate 
FIG. 61 F. Hoffmann-La Roche Ltd Market Share 
FIG. 62 C.H. Boehringer Sohn AG & Co.KG Revenue and Growth Rate 
FIG. 63 C.H. Boehringer Sohn AG & Co.KG Market Share 
FIG. 64 Achaogen, Inc. Revenue and Growth Rate 
FIG. 65 Achaogen, Inc. Market Share 
FIG. 66 ALLERGAN Revenue and Growth Rate 
FIG. 67 ALLERGAN Market Share 
FIG. 68 Aquinox Revenue and Growth Rate 
FIG. 69 Aquinox Market Share 
FIG. 70 AstraZeneca Revenue and Growth Rate 
FIG. 71 AstraZeneca Market Share 
FIG. 72 Cipla Inc. Revenue and Growth Rate 
FIG. 73 Cipla Inc. Market Share 
FIG. 74 Bayer AG Revenue and Growth Rate 
FIG. 75 Bayer AG Market Share 
FIG. 76 Dr. Reddy's Laboratories Ltd. Revenue and Growth Rate 
FIG. 77 Dr. Reddy's Laboratories Ltd. Market Share 
FIG. 78 Lipella Pharmaceuticals Inc. Revenue and Growth Rate 
FIG. 79 Lipella Pharmaceuticals Inc. Market Share 
FIG. 80 MediciNova, Inc. Revenue and Growth Rate 
FIG. 81 MediciNova, Inc. Market Share 
FIG. 82 MerLion Pharmaceuticals GmbH Revenue and Growth Rate 
FIG. 83 MerLion Pharmaceuticals GmbH Market Share 
FIG. 84 Mylan N.V. Revenue and Growth Rate 
FIG. 85 Mylan N.V. Market Share 
FIG. 86 Novo Nordisk A/S Revenue and Growth Rate 
FIG. 87 Novo Nordisk A/S Market Share 
FIG. 88 Shionogi Inc. Revenue and Growth Rate 
FIG. 89 Shionogi Inc. Market Share 
FIG. 90 Urigen Revenue and Growth Rate 
FIG. 91 Urigen Market Share 
FIG. 92 Zavante Therapeutics, Inc. Revenue and Growth Rate 
FIG. 93 Zavante Therapeutics, Inc. Market Share 
FIG. 94 Market Dynamics 
FIG. 95 Global Urinary Tract Infection Therapeutics – Value Chain Analysis 
FIG. 96 Technology Roadmap and Timeline 
FIG. 97 Market Attractiveness Analysis – By Age Group 
FIG. 98 Market Attractiveness Analysis – By Indication 
FIG. 99 Market Attractiveness Analysis – By Drug Type 
FIG. 100 Market Attractiveness Analysis – By Distribution Channel 
FIG. 101 Market Attractiveness Analysis – By Region 
FIG. 102 Market Channel 
FIG. 103 Marketing Channel Development Trend 
FIG. 104 Growth in World Gross Product, 2009-2019

    List of Tables

    TABLE 1 Global Urinary Tract Infection Therapeutics Market, 2020 & 2027 (USD Million) 
TABLE 2 Global Urinary Tract Infection Therapeutics market, by Age Group, 2017-2027 (USD Million) 
TABLE 3 Global Urinary Tract Infection Therapeutics market, by Indication, 2017-2027 (USD Million) 
TABLE 4 Global Urinary Tract Infection Therapeutics market, by Distribution Network, 2017-2027 (USD Million) 
TABLE 5 Global Urinary Tract Infection Therapeutics market, by Drug Group, 2017-2027 (USD Million) 
TABLE 6 Global Urinary Tract Infection Therapeutics market, by Region, 2017-2027 (USD Million) 
TABLE 7 North America Urinary Tract Infection Therapeutics Market, by Age Group, 2017-2027 (USD Million) 
TABLE 8 North America Urinary Tract Infection Therapeutics Market, by Indication, 2017-2027 (USD Million) 
TABLE 9 North America Urinary Tract Infection Therapeutics Market, by Distribution Network, 2017-2027 (USD Million) 
TABLE 10 North America Urinary Tract Infection Therapeutics Market, by Drug Group, 2017-2027 (USD Million) 
TABLE 11 Europe Urinary Tract Infection Therapeutics Market, by Age Group, 2017-2027 (USD Million) 
TABLE 12 Europe Urinary Tract Infection Therapeutics Market, by Indication, 2017-2027 (USD Million) 
TABLE 13 Europe Urinary Tract Infection Therapeutics Market, by Distribution Network, 2017-2027 (USD Million) 
TABLE 14 Europe Urinary Tract Infection Therapeutics Market, by Drug Group, 2017-2027 (USD Million) 
TABLE 15 Asia Pacific Urinary Tract Infection Therapeutics Market, by Age Group, 2017-2027 (USD Million) 
TABLE 16 Asia Pacific Urinary Tract Infection Therapeutics Market, by Indication, 2017-2027 (USD Million) 
TABLE 17 Asia Pacific Urinary Tract Infection Therapeutics Market, by Distribution Network, 2017-2027 (USD Million) 
TABLE 18 Asia Pacific Urinary Tract Infection Therapeutics Market, by Drug Group, 2017-2027 (USD Million) 
TABLE 19 Latin America Urinary Tract Infection Therapeutics Market, by Age Group, 2017-2027 (USD Million) 
TABLE 20 Latin America Urinary Tract Infection Therapeutics Market, by Indication, 2017-2027 (USD Million) 
TABLE 21 Latin America Urinary Tract Infection Therapeutics Market, by Distribution Network, 2017-2027 (USD Million) 
TABLE 22 Latin America Urinary Tract Infection Therapeutics Market, by Drug Group, 2017-2027 (USD Million) 
TABLE 23 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Age Group, 2017-2027 (USD Million) 
TABLE 24 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Indication, 2017-2027 (USD Million) 
TABLE 25 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Distribution Network, 2017-2027 (USD Million) 
TABLE 26 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Drug Group, 2017-2027 (USD Million) 
TABLE 27 Global Urinary Tract Infection Therapeutics Market - Company Revenue Analysis 2017-2019 (USD Million) 
TABLE 28 Global Urinary Tract Infection Therapeutics Market - Company Revenue Share Analysis 2017-2019 (%) 
TABLE 29 Acquisitions and Mergers 
TABLE 30 New Product/Service Launch 
TABLE 31 Research & Development Activities 
TABLE 32 Market Drivers
TABLE 33 Market Restraints
TABLE 34 Market Opportunities

Industry Major Market Players

  • Achaogen
  • Allergen
  • Aquinox
  • AstraZeneca
  • Almirall
  • S.A
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla
  • C.H. Boehringer Sohn
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline plc.
  • Janssen Global Services
  • LLC
  • Lipella Pharmaceuticals
  • Lupin Ltd.
  • MediciNova
  • MerLion Pharmaceuticals
  • Merck & Co.Inc
  • Novo Nordisk
  • Novartis
  • Pfizer
  • Sun Pharmaceutical Industries
  • Shionogi
  • Teva Pharmaceutical Industries
  • Urigen
  • Zavante Therapeutics.

paypal
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors